Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Tiny study tracks enzyme levels in kids with rare disease before and after transplant

NCT ID NCT05634512

First seen Nov 01, 2025 · Last updated Jun 18, 2026 · Updated 32 times

Summary

This study watches how the enzyme drug laronidase moves through the bodies of 13 children with MPS IH (a rare genetic disease) before and after they get a stem cell transplant. The goal is to learn what affects drug levels, not to test a new treatment. Children aged 0-3 who are already scheduled for transplant and enzyme therapy can join.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC CELL TRANSPLANTATION are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • University of Minnesota Masonic Cancer Center

    Minneapolis, Minnesota, 55455, United States

Conditions

The condition(s) this trial relates to.

Hurler syndrome Mucopolysaccharidosis I mucopolysaccharidosis type 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.